{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:49:49Z","timestamp":1789055389142,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.intimp.2026.116453","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:01:13Z","timestamp":1772643673000},"page":"116453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Antigen-induced IL-12 potentiates piggyBac-engineered HER2-CAR-T cells against gastric cancer"],"prefix":"10.1016","volume":"175","author":[{"given":"Jinping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116453_bb0005","first-page":"26","article-title":"Epidemiology of gastric cancer: global trends, risk factors and prevention","volume":"14","author":"Rawla","year":"2019","journal-title":"Przeglad Gastroenterologiczny"},{"key":"10.1016\/j.intimp.2026.116453_bb0010","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1002\/cam4.3892","article-title":"Chinese and global burdens of gastric cancer from 1990 to 2019","volume":"10","author":"He","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2026.116453_bb0015","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3390\/curroncol29030131","article-title":"Immunotherapy in gastric cancer","volume":"29","author":"H\u00f6gner","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.intimp.2026.116453_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.36","article-title":"Gastric adenocarcinoma","volume":"3","author":"Ajani","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2026.116453_bb0025","article-title":"Recent progress and future perspectives of immunotherapy in advanced gastric cancer","volume":"13","author":"Jin","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116453_bb0030","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.semcancer.2022.05.015","article-title":"Neoadjuvant immunotherapy in gastrointestinal cancers - the new standard of care?","volume":"86","author":"Petricevic","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.intimp.2026.116453_bb0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/ags3.12184","article-title":"Advances in cancer immunotherapy for gastroenterological malignancy","volume":"2","author":"Kono","year":"2018","journal-title":"Ann. Gastroenterol. Surg."},{"key":"10.1016\/j.intimp.2026.116453_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153322","article-title":"Immunotherapy of gastric cancer: past, future perspective and challenges","volume":"218","author":"Xie","year":"2021","journal-title":"Pathol. Res. Pract."},{"issue":"4","key":"10.1016\/j.intimp.2026.116453_bb0045","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10120-020-01090-4","article-title":"Current status of immune checkpoint inhibitors for gastric cancer","volume":"23","author":"Kono","year":"2020","journal-title":"Gastric Cancer: Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc."},{"key":"10.1016\/j.intimp.2026.116453_bb0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.116453_bb0055","doi-asserted-by":"crossref","unstructured":"Janjigian Y, Kawazoe A, Ya\u00f1ez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y et al.: The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600 (72021) 727\u2013730. https:\/\/doi.org\/10.1038\/s41586-021-04161-3.","DOI":"10.1038\/s41586-021-04161-3"},{"key":"10.1016\/j.intimp.2026.116453_bb0060","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/JLB.5RU1221-675R","article-title":"Analysis of potential biomarkers of response to IL-12 therapy","volume":"112","author":"Schwarz","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2026.116453_bb0065","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.116453_bb0070","doi-asserted-by":"crossref","unstructured":"Otani T, Nakamura S, Toki M, Motoda R, Kurimoto M, Orita K: Identification of IFN-\u03b3-gamma-producing cells in IL-12\/IL-18-treated mice. Cell. Immunol. 198 (199) 111\u2013119. https:\/\/doi.org\/10.1006\/cimm.1999.1589.","DOI":"10.1006\/cimm.1999.1589"},{"key":"10.1016\/j.intimp.2026.116453_bb0075","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.116453_bb0080","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116453_bb0085","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.leukres.2009.01.020","article-title":"Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the eastern cooperative oncology group","volume":"33","author":"Lacy","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.intimp.2026.116453_bb0090","article-title":"Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models","volume":"14","author":"Yang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116453_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952231","article-title":"IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116453_bb0100","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-21-4384","article-title":"Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma","volume":"28","author":"Meister","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116453_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121341","article-title":"IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy","volume":"281","author":"Luo","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.intimp.2026.116453_bb0110","first-page":"2651","article-title":"Construction of human IL-12 gene vector and its expression study in T cells","volume":"35","author":"Zou Yunlian","year":"2019","journal-title":"Chin. J. Immunol."},{"key":"10.1016\/j.intimp.2026.116453_bb0115","doi-asserted-by":"crossref","unstructured":"Tanner M, Hollm\u00e9n M, Junttila T, Kapanen A, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Annals of oncology : official journal of the European society for Med. Oncol.16 (2005) 273\u2013278. https:\/\/doi.org\/10.1093\/annonc\/mdi064, Ann. Oncol.","DOI":"10.1093\/annonc\/mdi064"},{"key":"10.1016\/j.intimp.2026.116453_bb0120","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116453_bb0125","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.19.03077","article-title":"Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction Cancer: WJOG7112G (T-ACT study)","volume":"38","author":"Makiyama","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116453_bb0130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","article-title":"Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)","volume":"22","author":"Seo","year":"2019","journal-title":"Gastric Cancer: Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc."},{"key":"10.1016\/j.intimp.2026.116453_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13020167","article-title":"IL-12 family cytokines in cancer and immunotherapy","volume":"13","author":"Mirlekar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.116453_bb0140","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1002\/cam4.2361","article-title":"Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12","volume":"8","author":"Chi","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2026.116453_bb0145","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.116453_bb0150","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Vipul Bhatia","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116453_bb0155","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ymthe.2021.10.011","article-title":"IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors","volume":"30","author":"Hombach","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.116453_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156758","article-title":"Optimizing CAR-T cell culture: differential effects of IL-2, IL-12, and IL-21 on CAR-T cells","volume":"184","author":"Zhang","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2026.116453_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799206","article-title":"Single-cell analysis of target antigens of CAR-T reveals a potential landscape of \"on-target, off-tumor toxicity\"","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116453_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01508-3","article-title":"Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models","author":"Sasaki","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.intimp.2026.116453_bb0175","article-title":"Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment","volume":"21","author":"Yang","year":"2023","journal-title":"J. Transl. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:14:52Z","timestamp":1777619692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926002973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"alternative-id":["S1567576926002973"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116453","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antigen-induced IL-12 potentiates piggyBac-engineered HER2-CAR-T cells against gastric cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116453"}}